143 results
8-K
IDYA
Ideaya Biosciences Inc
12 Mar 24
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
6:04am
as a monotherapy or combination agent.
The foregoing is only a summary description of the terms of the Agreement, does not purpose to be complete
S-8
IDYA
Ideaya Biosciences Inc
20 Feb 24
Registration of securities for employees
4:31pm
(the “Commission”) for the purpose of registering an additional 3,251,967 shares of common stock, par value $0.0001 per share (“common stock”), of IDEAYA … December 31, 2023 and any amendments or reports filed for the purpose of updating such description.
All documents that the Registrant subsequently files
8-K
EX-10.1
ibnzf rbbasn
19 Jan 24
Entry into a Material Definitive Agreement
5:18pm
424B5
vmo1dwjora83dov2n
19 Jan 24
Prospectus supplement for primary offering
5:15pm
8-K
m060tl3b3vqaet0awk3
4 Dec 23
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer
6:04am
8-K
dp70taxgtlb
17 Nov 23
Entry into a Material Definitive Agreement
6:02am
8-K
EX-1.1
39zzxyypmja
27 Oct 23
Other Events
4:23pm
8-K
EX-4.1
0lcuqib4ls9
27 Oct 23
Other Events
4:23pm
424B5
hoa8up3
25 Oct 23
Prospectus supplement for primary offering
9:45pm
424B5
kgct72aip546x 5gyvss
24 Oct 23
Prospectus supplement for primary offering
5:26pm